Bio-Techne Corporation has introduced new AI-engineered proteins to enhance reproducibility and performance in advanced cell culture and cell therapy workflows. These proteins, including heat-stable fibroblast growth factors and hyperactive interleukins, improve stability and activity, addressing challenges in scaling cell therapies from research to manufacturing. Early users report better cell expansion and reduced costs, highlighting the potential for more consistent and scalable therapeutic development. This expansion strengthens Bio-Techne's role in supporting regenerative medicine and cell therapy manufacturing at commercial scale.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
Brodsky & Smith LLC has announced investigations into whether the boards of LCI Industries, Iridium Communications, Bio-Techne Corporation, and Arcosa breached their fiduciary duties during recent merger agreements. The investigations focus on whethe...
